skip to Main Content

OncoSil Medical Reveals Positive Data from Pancreatic Cancer Clinical Study

Newsfeed image, light gray text on dark gray background
OncoSil Medical Ltd’s pancreatic cancer clinical study has demonstrated significant local disease control with up to 73% reduction in tumour volume observed 4 weeks post implant.

The company’s lead product, OncoSil™, is a targeted radioactive isotope, implanted directly into a patient’s pancreatic tumour via an endoscopic ultrasound.

Treatment with OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.

OncoSil has provided an overview of early study results at the European Association of Nuclear Medicine (EANM) Congress, which took place in Vienna on 21 October 2017. Read more . . .

Back To Top